PRESCRIPTION COST AMENDMENTS
2022 GENERAL SESSION
STATE OF UTAH
Chief Sponsor: Evan J. Vickers
House Sponsor:
LONG TITLE
General Description:
This bill amends the Insurance Code.
Highlighted Provisions:
This bill:
<ul><li>defines terms;</li></ul>
<ul> <li>prohibits a health benefit plan from excluding payments made on behalf of an</li> </ul>
insured when determining whether the insured has satisfied the plan's cost sharing
requirements; and
<ul> <li>requires a health benefit plan to apply certain payments by an insured for</li> </ul>
prescription drugs to the insured's deductible and maximum out-of-pocket limit.
Money Appropriated in this Bill:
None
Other Special Clauses:
None
<b>Utah Code Sections Affected:</b>
ENACTS:
<b>31A-22-657</b> , Utah Code Annotated 1953



27

Section 1. Section 31A-22-657 is enacted to read:

S.B. 139 01-26-22 2:25 PM

28	31A-22-657. Cost sharing Payments made on behalf of an insured Payments
29	for certain drugs not paid for by the insurer.
30	(1) As used in this section:
31	(a) (i) "Cost sharing requirement" means copayments, coinsurance, deductibles, and
32	other requirements for payment an insured is required to make under the provisions of a health
33	benefit plan.
34	(ii) "Cost sharing requirement" does not include premiums.
35	(b) "Generic equivalent" means a drug product that is designated in the Approved Drug
36	Products with Therapeutic Equivalence Evaluations prepared by the Center for Drug
37	Evaluation and Research of the United States Food and Drug Administration as:
38	(i) the therapeutic equivalent of another drug product; and
39	(ii) an "A" rated drug product.
40	(c) "Qualified prescription drug" means a prescription drug as defined in Section
41	<u>58-17b-102</u> for which:
42	(i) there is no generic equivalent; or
43	(ii) a health benefit plan insured has:
44	(A) received preauthorization from the health benefit plan in accordance with Section
45	31A-22-650;
46	(B) completed the health benefit plan's step therapy protocol for the prescription drug;
47	<u>or</u>
48	(C) received authorization for payment as the result of an internal or independent
49	review in accordance with Section 31A-22-629.
50	(2) (a) Except as provided in Subsection (2)(b), when determining whether an insured
51	has satisfied a health benefit plan's cost sharing requirement, the health benefit plan may not
52	exclude payments made on behalf of the insured for a qualified prescription drug.
53	(b) If application of Subsection (2)(a) would result in health savings account
54	ineligibility under 26 U.S.C. Sec. 223, payments made on behalf of an insured for a qualified
55	prescription drug that is not preventive care under 26 U.S.C. Sec. 223(c)(2)(C) shall apply to
56	the insured's health savings account-qualified high deductible health plan deductible only after
57	the insured has satisfied the minimum deductible under 26 U.S.C. Sec. 223.
58	(3) (a) When determining whether an insured has satisfied a health benefit plan's

01-26-22 2:25 PM S.B. 139

59	deductible or maximum out-of-pocket limit, the health benefit plan shall, upon request by the
60	insured, include payments made by the insured for a qualified prescription drug which was:
51	(i) eligible for payment by the health benefit plan; and
52	(ii) not paid for by the health benefit plan.
63	(b) An insurer that offers a health benefit plan shall provide an insured with a method
54	<u>for:</u>
65	(i) making the request permitted under Subsection (3)(a); and
66	(ii) reporting and documenting to the insurer's satisfaction payments made by the
67	insured for a qualified prescription drug described under Subsection (3)(a).